Other Industry Events

Jump To:

Regenerative Medicine Crossroad in Tokyo #10 (RMCR#10)

September 25, 2019

“Regenerative Medicine Crossroad® in Tokyo #10” on September 25, 2019, Tokyo, Japan

– A Can’t-miss Opportunity to Meet Your Business Partners in Japan –

Gene Therapy for Rare Disorders Europe

October 15–17, 2019

Dedicated to Realising the Commercial Potential of Gene Therapies

Biofabrication 2019

October 20–22, 2019

The International Conference on Biofabrication (Biofabrication 2019) is the annual meeting of the International Society for Biofabrication.

From Stem Cell Biology to New Therapies

November 6–8, 2019

Join the ISSCR for From Stem Cell Biology to New Therapies, 6-8 November 2019 in Toronto, Canada. This international symposium is co-sponsored by BlueRock Therapeutics. Learn more and register at www.isscr.org/toronto2019

BIO-Europe® 2019 - 25th Annual International Partnering Conference

November 11–13, 2019

The 25th annual BIO-Europe® event is the largest biotechnology partnering conference held in Europe. Over 4,350 global decision makers from biotechnology, pharma and finance annually attend BIO-Europe to identify new business opportunities and develop strategic relationships. Business development executives and dealmakers consider BIO-Europe a must-attend event and an effective business strategy enabling them to meet and present to numerous potential partners. BIO-Europe features the industry’s most advanced web-based partnering system enabling delegates from all parts of the biotechnology value chain to quickly identify, engage and enter into strategic relationships that drive their business successfully forward.
BIO-Europe’s world-class workshops, panels and active exhibition along with thousands of prescheduled one-to-one meetings make this event an unrivaled forum for companies across the biotech value chain to meet and do business. Learn more here https://ebdgroup.knect365.com/bioeurope/.

World Orphan Drug Congress

November 12–14, 2019

The 10th is taking place 12th–14th November, 2019 in Barcelona, Spain; and is not an event to be missed.

Now recognised as the largest and most established European orphan drug event, we are once again proud to deliver another outstanding speaker line-up and a content-filled agenda that represents the whole orphan drug landscape. The 10th annual event will address the strategic and commercial aspects of bringing new treatments to patients who suffer from rare diseases.

For 2019 we will be expanding the meeting further with a dedicated co-conference on Cell & Gene Therapy and even more dedicated content and tracks than ever before on Clinical/Product Development, Market Access & Pricing, Manufacture, Science & Strategy, Pitch & Partner and Precision Medicine. 

We will also continue the highly popular Pre-Congress Workshops. So make sure you’re there this November in Barcelona.

Download Full agenda here

Book your ticket here

2019 TERMIS-AM Conference

December 2–5, 2019

The 2019 Conference of the Tissue Engineering and Regenerative Medicine International Society – Americas Chapter (TERMIS-AM) will be held in Orlando in December.  The theme of the conference is “Transversal, Translational and Transformative.” Transversal knowledge. Translational approaches. Transformative solutions. We will strive to create an agenda that fosters integrative and circular routes of thinking, inspiring young minds, transforming old visions, and accelerating clinical solutions.

FDA/CMS Summit 2019

December 3–4, 2019

Your Window into Emerging FDA and CMS Regulatory Policies Affecting Life Sciences

CBI’s FDA/CMS Summit draws the highest leadership at the FDA and CMS and delivers best available information on FDA and CMS priorities, policy changes, evidence-based practice, federal review processes on various areas of biopharma like CDER, CBER, CDRH and the most cutting-edge advances in healthcare and technology. This event is geared to the information needs of C-Suite biopharmaceutical executives, Directors/VPs of Regulatory/Government Affairs, FDA regulators, consultants, law firms, PhRMA and big pharmaceutical companies.